X-Chem Expands Strategic Collaboration With Orion Pharma to Accelerate Orion's Early Drug Discovery From Hit to Candidate
This expanded engagement reflects years of collaboration and trust between the two companies. Through previous work together, X-Chem has delivered high-value insights and differentiated chemical matter to Orion's discovery teams. The renewed commitment is a strategic step forward in advancing small molecule discovery with greater efficiency and precision.
'X-Chem's flexible business model is enabling us to evaluate both new targets and revisit existing programs with enhanced tools,' said Heikki Käsnänen, Head of Molecular Prospecting and Modeling at Orion Pharma. 'We are applying their DEL-based screening technologies, as well as their expertise in AI and computational chemistry, to explore alternative routes for optimization. This approach is further supported by synthetic and medicinal chemistry to expand hit series and advance toward lead optimization.'
X-Chem's platform combines advanced DEL capabilities with ArtemisAI, its proprietary artificial intelligence engine trained on the world's largest DEL datasets. Together with in-house computational and medicinal chemistry teams, the company helps partners make informed decisions earlier in the discovery process, reducing risk and improving outcomes.
'Our goal is to empower innovative companies like Orion to efficiently identify and progress high-quality drug candidates,' said Karen Lackey, CEO at X-Chem. 'This expanded partnership reflects a strong foundation of trust and a shared commitment to overcoming complex challenges in early discovery. By aligning our scientific expertise, we can help Orion move from hit to candidate with speed and confidence.'
The collaboration reinforces X-Chem's position as a discovery partner with capabilities that extend well beyond traditional screening, offering end-to-end discovery solutions designed to accelerate success in small molecule drug discovery.
About X-Chem
X-Chem is a pioneer in data-driven small molecule drug discovery. By integrating DNA-encoded library (DEL) technology, artificial intelligence, and medicinal chemistry, X-Chem accelerates the path from target to clinical candidate. With a proven track record across complex targets and therapeutic areas, X-Chem delivers smarter hits, faster timelines, and reduced early-stage risk for pharmaceutical and biotech partners. Learn more at www.x-chemrx.com.
About Orion Pharma
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki. Learn more at www.orionpharma.com.
Media Contact:
Alli Cooke
[email protected]
616.258.5769
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Veidekke acquires tunnel construction contract for Gothenburg's West Link Project
Veidekke has received a contract from the Swedish Transport Administration to build the Stora Hamnkanalen tunnel, a component of the West Link Project in central Gothenburg. With an initial contract value of Skr280m ($29.3m), the project involves the creation of a tunnel comprising both concrete and rock sections, measuring approximately 54m and 16m in length, respectively. This tunnel will traverse the Stora Hamnkanalen near its outlet into the Göta älv. The commencement of the project is immediate, with an anticipated completion date set for mid-2029. The Stora Hamnkanalen tunnel represents the final construction contract within the Haga stage of the West Link Project, which aims to establish a strong commuter and regional railway network for the city of Gothenburg. Veidekke has also received a commission from OBOS, a Nordic cooperative building association, for the rehabilitation of its former head office at Hammersborg Torg in Oslo, Norway. This turnkey contract is valued at around Nkr300m, excluding VAT. With OBOS having recently relocated to Construction City at Ulven, the collaboration with Veidekke will focus on upgrading the old head office to align with contemporary standards and the expectations of new tenants. The renovation project encompasses an interior overhaul of around 17,500m² of office space, spread across two buildings of 12 and four floors, a reception building, and shared basements on three levels. The refurbished premises will feature reduced energy consumption, new technical installations, modern office spaces, meeting rooms, a canteen, a training room, and changing facilities. Furthermore, the existing underground parking garage will be rehabilitated while new bicycle parking facilities will be introduced. With construction work starting immediately, the handover of the renovated premises is scheduled for the second and third quarters of 2026. Veidekke's recent projects also include the construction of the multipurpose Bjarg Arena in Bergen, Norway, for the Bjarg Sports Club. "Veidekke acquires tunnel construction contract for Gothenburg's West Link Project" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 hours ago
- Associated Press
Germany and allies to send major military aid package to Ukraine using new NATO supply line
BERLIN (AP) — Germany announced on Wednesday that it will work with a group of Ukraine's Western backers to supply a package of military aid to the war-ravaged country worth up to $500 million using a new NATO supply line. Earlier this month, NATO started coordinating regular deliveries of large weapons packages to Ukraine after the Netherlands said that it would provide air defense equipment, ammunition and other military aid worth 500 million euros ($582 million). Sweden announced the following day that it would contribute $275 million to a joint effort along with its Nordic neighbors Denmark and Norway to provide $500 million worth of air defenses, anti-tank weapons, ammunition and spare parts. Germany's foreign and defense ministries said the support is focused on equipment like 'critical air defense capabilities. These are urgently needed to defend against Russia's ongoing air strikes, which are killing more and more civilians throughout Ukraine.' The United Nations has said that Russia's relentless pounding of urban areas behind the front line has killed more than 12,000 Ukrainian civilians. Two deliveries of equipment, most of it bought in the United States, were scheduled for this month, although the Nordic package was more likely to arrive in September. Germany did not name the group of countries it would be working with. The equipment is supplied based on Ukraine's priority needs on the battlefield. NATO allies then locate the weapons and ammunition and send them on. Germany has delivered or pledged military support to Ukraine worth around 40 billion euros ($47 billion) since Russia launched its full-scale invasion in February 2022.
Fast Company
3 hours ago
- Fast Company
Most people are using ChatGPT totally wrong—and OpenAI's CEO just proved it
How did you react to the August 7 release of GPT-5, OpenAI's latest version of ChatGPT? The company behind the model heralded it as a world-changing development, with weeks of hype and a glitzy livestreamed unveiling of its capabilities. Social media users' reactions were more muted, marked by confusion and anger at the removal of many key models people had grown attached to. In the aftermath, CEO Sam Altman unwittingly revealed why the gulf between OpenAI's expectations for GPT-5's reception and the reality was so wide. It turns out that large numbers of us aren't using AI to its fullest extent. In a post on X explaining why OpenAI appeared to be bilking fee-paying Plus users (full disclosure: that includes me)—who hand over $20 per month to access the second-highest tier of the model—by drastically reducing their rate limits to the chatbot, Altman revealed that just 1% of nonpaying users queried a reasoning model like o3 before GPT-5's release. Among paying users, only 7% did. Reasoning models are those that 'think' through problems before answering them (though we should never remove those air quotes: AI models are not human, and do not act as humans do). Not using them—as was the case with the overwhelming majority of users, paying and nonpaying alike—is like buying a car, using only first and second gear, and wondering why it's not easy to drive, or going on a quiz show and blurting out the first thing that comes to mind for every question. Many users prioritize speed and convenience over quality in AI chatbot interactions. That's why so many lamented the loss of GPT-4o, a legacy model that was later restored to paying ChatGPT users after a concerted campaign. But when you're querying a chatbot for answers, you want good ones. It's better to be a little slower—and often it is only a little—and right than quick and completely wrong. Reasoning models are built to spend more computational effort planning, checking, and iterating before answering. This extra deliberation improves results on tasks where getting the logic right matters. But it's slower and costlier, which is why providers tend to offer the 'non-thinky' versions first and require users to opt in via a drop-down box for alternatives. Then there's OpenAI's previously impenetrable habit of naming models—a problem GPT-5 attempted to fix, not altogether successfully. Users still can't easily tell whether they're getting the 'good thinky' GPT-5 or the less-capable version. After receiving complaints, the company is now tweaking that. To me, waiting a minute rather than a second isn't an issue. You set an AI model off and do something else while you wait. But evidently, it's a wait too long for some. Even after GPT-5's release—where the difference between 'flagship model' GPT-5 and GPT-5 thinking, which offers to 'get more thorough answers,' is more obvious—only one in four paying users are asking for thoroughness. This quickly tossed-out data answers one big question I had about AI adoption: Why do only a third of Americans who have ever used a chatbot say it's extremely or very useful (half the rate among AI experts) and one in five say it's not useful at all (twice the rate among experts)? The answer is clearer now: Most folks are using AI wrong. They're asking a chatbot to handle tough, multipart questions without pausing for thought or breath. They're blurting out 'What is macaroni cheese' on The Price is Right and '$42' on Jeopardy! So if you're going to try a chatbot, take advantage of OpenAI's moves to keep users from canceling their subscriptions by opening up more access to models. Set them 'thinking' while remembering they're not actually doing that—and see if you stick around. It's the right way to use generative AI.
